Esmo 2022 – Trodelvy’s improving trajectory might not matter much
Later cuts of Tropics-02 make for better reading, but in Her2-driven breast cancer Gilead’s Trodelvy will remain a footnote to Enhertu.
Esmo 2022 – last-minute Kras entry takes centre stage
Amgen’s confirmatory Codebreak-200 trial will feature as a surprising late-breaker at Esmo’s presidential session.
Go or no go? J&J’s bispecific FDA first
Pdufa decisions also beckon for Amicus, Acadia and Bluebird.
Padcev has the front line in its sights
But the main question for deal-hungry investors will be what this means for the chances of Merck & Co buying out Seagen.
The Cytomx paradox
Failure of the company’s in-house lead raises questions about the viability of its extensively partnered probody technology.
